Several trials showed similar PFS benefits over chemotherapy using ALK-TKIs between smokers and never-smokers for patients with treatment-naïve advanced stage ALK mutation-positive lung cancer (10, 11, 14). This evidence concerns the gene ALK and lung carcinoma.